HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health, Inc. is anticipated to report earnings per share (EPS) of $0.11 for the current quarter, reflecting a substantial 120% increase from the same period last year. Revenue is projected ...

One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...